Yan Zhang, PhD, Mission Bio, San Francisco, CA, describes the capabilities of the Tapestri Platform, which utilizes single-cell multi-omics technology. Tapestri can accurately measure the efficacy and safety of cell and gene therapies by monitoring genomic and protein changes at a single-cell level. The platform can additionally elucidate mechanisms of relapse or resistance to cancer therapies. Resistance can occur due to mutations or changes in the tumor microenvironment, and the platform enables analysis of resistant cells to gain insight into disease progression. This interview took place at Meeting on the Mesa 2021.